« U.S. Supreme Court to Review Prescription Privacy Laws | Main | Defining the Success of E-Health; How a Research Study Went Wrong »

Comments

brochure printing

It would be unethical to refuse treatment to patients in the placebo group. Or a trial could be interrupted if the data available to the DSMB indicated that it would be very unlikely for the drug to show any benefit, even if the trial continued.

The comments to this entry are closed.

Corporate Underwriters





  •  
     

     
     
     
     
     
     

Search Lab Soft News

  • Google

    WWW
    labsoftnews.typepad.com

Subscribe to Lab Soft News (Email and RSS Feeds)

Your email address:


Powered by FeedBlitz

May 2020

Sun Mon Tue Wed Thu Fri Sat
          1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30
31            
Blog powered by Typepad
Member since 12/2005